ProTrials Research, Inc. today announced that it has been awarded top honors in the 5th annual Stevie Awards for Women in Business.
ProTrials Wins Stevie® Award For Women In Business
Selection recognizes ProTrials’ commitment to client service
Mountain View, CA and New York – November 19, 2008 – ProTrials Research, Inc.TM, a leader in the clinical research organization industry, today announced that it has been awarded top honors in the 5th annual Stevie Awards for Women in Business. The company won for Best Overall Company of the Year – Service Businesses – up to 100 Employees.
ProTrials beat out nine other finalists in its category and was among more than 1,200 nomination submittals in 50 categories worldwide from organizations of all sizes and in virtually every industry. Both Jodi Andrews, ProTrials Co-founder and CEO, and Inger Arum, ProTrials Co-founder and President, accepted the Stevie in a gala event at New York City’s Marriott Marquis Hotel on November 14.
“A Stevie is an important symbol of a business’s successful accomplishments and we are honored to have ProTrials selected,” said Jodi Andrews. “It’s satisfying that the judges recognized how the company is continuing to provide unique and outstanding services to its clients in such a challenging economic climate.”
The 2008 Stevie Awards for Women in Business is an international competition recognizing the accomplishments of outstanding women executives, business owners, and the organizations they run. The Stevies have been hailed as the world’s premier business awards with its prestigious American Business AwardsSM being called “the business world’s own Oscars” (New York Post, April 27, 2005).
“This award validates what Jodi and I already recognize – ProTrials provides clients the best possible service,” Arum added.
ProTrials is owned and operated by two women -- Jodi Andrews and Inger Arum. It recently made the Inc. 5000 list of the fastest-growing private companies in the United States and ranked seventh on the Silicon Valley/San Jose Business Journal’s list of the area’s Top 50 Women-Owned Businesses for 2008. This year, it attained certification by the Women’s Business Enterprise National Council, an elite group of women-owned and operated businesses.
More details about The Stevie Awards for Women in Business and the list of honorees are available at www.stevieawards.com/women <http://www.stevieawards.com/women>
About ProTrials Research, Inc.
Founded in 1996, ProTrials Research, Inc. is a specialized contract research organization (CRO) with regional clinical research associates and project managers based throughout North America, Canada, and Europe. The company works with clients in the pharmaceutical, biotechnology and medical device industries, providing cost-effective site monitoring, project management and associated clinical operations services. ProTrials is headquartered in Mountain View, California. For more information, visit www.protrials.com <http://www.protrials.com/> or call (650) 864-9180.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.